IPA 5MG/CJC 5MG
$28.00
Technical Specifications
- Product Name: Ipamorelin / CJC-1295 No DAC Blend
- Scientific Description: Ipamorelin and Modified GRF(1–29) Two-Peptide Research Blend
- Common Name: IPA / CJC-1295 No DAC
- Peptide Classification: Synthetic Dual-Peptide Receptor-Signaling Research Blend
- Primary Research Areas: GHS-R1a Signaling, GHRH-Receptor Signaling, Cyclic AMP Pathways, Intracellular Calcium Signaling, and Peptide Characterization
- Research Components: Ipamorelin and CJC-1295 No DAC (Modified GRF 1–29)
- Blend Composition: 5MG Ipamorelin / 5MG CJC-1295 No DAC
- Mass Ratio: 1:1 by Labeled Mass
- Total Research Quantity: 10MG
- Appearance: White to Off-White Lyophilized Powder
- Intended Use: Laboratory Research Only
In stock
🔬 For Laboratory Research Use Only.
Not for human consumption, medical, veterinary, or household use.
By purchasing you agree to our
Terms and
Refund Policy.
Contains 5MG Ipamorelin and 5MG CJC-1295 No DAC for a total nominal research quantity of 10MG
Combines a GHS-R1a-associated pentapeptide with a modified GHRH(1–29) receptor analogue
Uses Modified GRF(1–29) without the albumin-binding drug-affinity-complex extension
Prepared and shipped from our Texas facility with fast U.S. order processing
A defined lyophilized dual-peptide research format containing 5MG of Ipamorelin and 5MG of CJC-1295 No DAC, also identified more precisely as Modified GRF(1–29), investigated in controlled laboratory systems involving GHS-R1a signaling, GHRH-receptor biology, cyclic AMP pathways, intracellular calcium signaling, receptor interaction, pituitary-cell models and multi-component analytical characterization.
IPA / CJC-1295 No DAC 10MG Research Summary
IPA / CJC-1295 No DAC 10MG is a dual-peptide research blend containing 5MG of Ipamorelin and 5MG of Modified GRF(1–29).
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue investigated primarily through the growth hormone secretagogue receptor 1a.
Growth hormone secretagogue receptor 1a is commonly abbreviated GHS-R1a and is also described as the signaling form of the ghrelin receptor.
The compound commonly marketed as CJC-1295 No DAC is more precisely identified as Modified GRF(1–29).
Modified GRF(1–29) is a synthetic 29-amino-acid analogue of the biologically active N-terminal region of human growth hormone-releasing hormone.
Modified GRF(1–29) is investigated primarily through the growth hormone-releasing hormone receptor.
The growth hormone-releasing hormone receptor is commonly abbreviated GHRH-R or GHRHR.
Ipamorelin and Modified GRF(1–29) act through separate receptor systems that may converge on pituitary somatotroph biology and growth hormone-associated secretion.
Ipamorelin is associated with GHS-R1a signaling, while Modified GRF(1–29) is associated with GHRH-receptor signaling.
The blend therefore represents two distinct upstream signaling pathways rather than two versions of the same peptide mechanism.
Combination research may examine whether simultaneous activation of GHS-R1a-associated and GHRH-receptor-associated pathways alters intracellular signaling, hormone-release amplitude, temporal response or downstream endocrine measurements.
A combined response greater than either peptide alone does not automatically establish true biological synergy.
Formal synergy requires comparison with a predefined additive-response model and inclusion of both individual peptide conditions.
Growth hormone secretion is physiologically pulsatile and is influenced by hypothalamic GHRH, somatostatin, ghrelin-associated signaling, nutritional state, circadian timing and endocrine feedback.
Research involving growth hormone release may therefore require serial sampling rather than reliance on one isolated measurement.
Downstream experimental endpoints may include cyclic AMP, intracellular calcium, growth hormone release, IGF-1, IGF-binding proteins, receptor activation, kinase signaling and gene-expression changes.
Ipamorelin should not be confused with Ibutamoren.
Ipamorelin is a peptide, whereas Ibutamoren, also known as MK-677, is a chemically distinct non-peptide compound.
Modified GRF(1–29) should not be treated as chemically identical to true CJC-1295 with DAC.
True CJC-1295 with DAC contains an additional reactive drug-affinity-complex structure designed to associate with serum albumin.
CJC-1295 No DAC lacks that DAC extension and is investigated as a separate molecular form.
The defined 5MG / 5MG blend may support replicate receptor assays, concentration-response experiments, time-course studies, endocrine signaling models, HPLC method development, LC-MS characterization and comparative peptide research.
IPA / CJC-1295 No DAC 10MG is supplied exclusively for controlled laboratory research and is not intended for human or veterinary administration.
Technical Specifications
IPA / CJC-1295 No DAC 10MG
Ipamorelin
CJC-1295 No DAC
Modified GRF(1–29)
5MG per vial
5MG per vial
10MG per vial
1:1 by labeled mass
Dual-peptide receptor-signaling research blend
Lyophilized dual-peptide research material
GHS-R1a signaling, GHRH-receptor signaling, second-messenger pathways and pituitary-model research
Growth hormone secretagogue receptor 1a
GHS-R1a
Growth hormone-releasing hormone receptor
GHRH-R or GHRHR
Five amino-acid residues
Twenty-nine amino-acid residues
Not present
Not present
C38H49N9O5
Approximately 711.9 g/mol
9831659
170851-70-4
C152H252N44O42
91976842
Tetrasubstituted GHRH(1–29) analogue
Hormone-release measurements, endocrine feedback markers and downstream signaling assays
HPLC, LC-MS, blend-ratio analysis and stability research
Dry lyophilized peptide blend
Laboratory research only
IPA / CJC-1295 No DAC 10MG contains two chemically distinct peptides with different sequences, molecular weights, chromatographic behavior and receptor systems. The 10MG designation represents 5MG of Ipamorelin plus 5MG of Modified GRF(1–29). Total blend mass must not be interpreted as 10MG of either individual component.
CJC-1295 No DAC Naming Clarification
The term CJC-1295 No DAC is widely used in the peptide research market but may create scientific ambiguity.
True CJC-1295 was developed as a modified GHRH analogue containing a drug-affinity-complex structure designed for prolonged association with serum albumin.
The peptide marketed as CJC-1295 No DAC generally corresponds to Modified GRF(1–29).
Modified GRF(1–29) is a tetrasubstituted analogue of human GHRH(1–29).
It lacks the reactive DAC extension used in true DAC-containing CJC-1295.
The non-DAC form therefore has a different chemical identity and research profile from CJC-1295 with DAC.
This page uses the familiar name CJC-1295 No DAC for product recognition while also identifying the component by the more precise scientific name Modified GRF(1–29).
Modified GHRH-related peptide containing a drug-affinity-complex structure associated with albumin binding.
Common research-market name generally used for Modified GRF(1–29).
More precise scientific name for the 29-residue GHRH analogue contained in this blend.
Modified GRF(1–29) does not contain the albumin-binding DAC extension.
Ipamorelin Amino-Acid Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NHâ‚‚
Ipamorelin is a synthetic pentapeptide containing five amino-acid residues.
The structure includes nonstandard amino-acid components and defined stereochemical configurations.
Aib identifies 2-aminoisobutyric acid.
His identifies histidine.
D-2-Nal identifies D-configured 2-naphthylalanine.
D-Phe identifies D-phenylalanine.
Lys-NHâ‚‚ identifies a C-terminal lysinamide structure.
The aromatic residues contribute hydrophobic and chromatographic characteristics.
The basic residues may contribute positive charge under many laboratory conditions.
Changes in residue stereochemistry, sequence order or terminal amidation create a chemically distinct analogue.
Modified GRF(1–29) Amino-Acid Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NHâ‚‚
Modified GRF(1–29) contains twenty-nine amino-acid residues.
It is based on the biologically active N-terminal 1–29 region of human growth hormone-releasing hormone.
The peptide contains substitutions commonly represented as D-Ala at position 2, Gln at position 8, Ala at position 15 and Leu at position 27.
These substitutions distinguish Modified GRF(1–29) from native human GHRH(1–29).
Human GHRH(1–29) is also commonly associated with the research name Sermorelin.
Modified GRF(1–29) retains the general receptor-active region while altering selected residues associated with peptide stability and enzymatic susceptibility.
The sequence terminates in an amide structure.
Modified GRF(1–29) contains no albumin-binding DAC extension.
Addition of the DAC-associated structure would produce a chemically different compound.
Molecular Characteristics
IPA / CJC-1295 No DAC 10MG combines a compact synthetic pentapeptide with a substantially larger 29-residue GHRH analogue.
Ipamorelin contains aromatic, basic and nonstandard amino-acid residues.
Modified GRF(1–29) contains a broader distribution of charged, polar and hydrophobic residues.
The two components differ significantly in molecular weight, peptide length, ionization behavior and chromatographic retention.
Equal labeled mass does not mean equal molecule number.
Because Ipamorelin has a lower molecular weight, 5MG of Ipamorelin contains more molecules than 5MG of Modified GRF(1–29).
Molar calculations should therefore be performed separately for each peptide.
Both peptides may produce singly or multiply protonated ions during electrospray-ionization mass spectrometry.
Modified GRF(1–29) is expected to display a broader multiply charged ion envelope because of its larger size and greater number of ionizable residues.
Surface adsorption, enzymatic cleavage and sample-processing loss may affect the recovered concentration of each component differently.
The blend contains chemically independent five-residue and twenty-nine-residue peptide components.
Equal mass quantities do not represent equal molar quantities.
Ipamorelin is associated with GHS-R1a, while Modified GRF(1–29) is associated with GHRH-R.
Each peptide may display distinct retention and ultraviolet-response characteristics.
Each component may generate a different mass-spectrometric charge-state distribution.
The Modified GRF(1–29) component lacks the albumin-binding DAC structure.
The peptides may differ in adsorption, degradation and sample-processing loss.
Changes in residue order, stereochemistry or terminal chemistry create different molecular forms.
Scientific Background
Growth hormone secretion is regulated by multiple hypothalamic and peripheral signaling systems.
Growth hormone-releasing hormone generally promotes pituitary somatotroph activation through the GHRH receptor.
Somatostatin generally inhibits growth hormone release through somatostatin-receptor pathways.
Ghrelin and synthetic growth hormone secretagogues may activate GHS-R1a-associated signaling.
Ipamorelin was developed within the growth hormone secretagogue research category.
Modified GRF(1–29) was developed from the receptor-active region of human GHRH.
Combining the peptides creates a model containing two distinct stimulatory receptor systems.
These systems may converge on pituitary hormone-release processes while remaining separate at the receptor level.
Research has examined growth hormone secretagogues and GHRH analogues through receptor assays, pituitary-cell models, second-messenger measurements, endocrine sampling and downstream signaling analyses.
Findings may depend on model type, receptor expression, endocrine state, timing, concentration and biological feedback.
Published findings do not establish that research-grade IPA / CJC-1295 No DAC materials are approved, safe or effective for personal use.
Ipamorelin Biology
Ipamorelin is investigated as a synthetic agonist of the growth hormone secretagogue receptor 1a.
GHS-R1a is a G-protein-coupled receptor associated with ghrelin signaling.
Receptor activation is commonly linked with Gq-family signaling, phospholipase C activation and intracellular calcium mobilization.
GHS-R1a signaling may influence pituitary somatotroph activity and growth hormone-associated secretion.
Ipamorelin is structurally distinct from endogenous ghrelin.
Similar receptor activity does not establish identical pharmacology across all models.
Potential experimental endpoints include receptor binding, calcium flux, intracellular signaling, receptor activation and receptor desensitization.
Receptor expression and basal signaling should be confirmed in cell-based models.
A negative result in a receptor-deficient system should not be interpreted as universal inactivity.
GHS-R1a antagonists, receptor-null cells or genetic silencing may help test receptor dependence.
Growth Hormone Secretagogue Receptor Research
Growth hormone secretagogue receptor 1a is the signaling form of the ghrelin receptor.
It is expressed in pituitary, hypothalamic and selected peripheral experimental systems.
GHS-R1a may display constitutive signaling activity in some laboratory models.
Constitutive activity may influence apparent baseline signaling and agonist-response measurements.
Receptor density may affect measured potency and maximal response.
Engineered cell lines may produce different signaling patterns from native pituitary cells.
Calcium-sensitive fluorescent probes may be used to evaluate rapid receptor activation.
Reporter assays may evaluate downstream transcriptional or second-messenger responses.
Receptor internalization and desensitization may influence repeated-exposure experiments.
Growth hormone secretagogue receptor 1a.
Ghrelin receptor.
G-protein-coupled receptor.
Gq-family signaling.
Phospholipase C, inositol-phosphate and calcium-associated signaling.
Ipamorelin.
Modified GRF(1–29) Biology
Modified GRF(1–29) is investigated as an analogue of the receptor-active N-terminal region of human growth hormone-releasing hormone.
The peptide interacts with the growth hormone-releasing hormone receptor in experimental systems.
The GHRH receptor is prominently associated with anterior pituitary somatotroph cells.
Receptor activation is commonly associated with Gs-protein signaling.
Gs activation may stimulate adenylyl cyclase and increase intracellular cyclic AMP.
Cyclic AMP may activate protein kinase A and downstream secretory or transcriptional pathways.
GHRH-receptor signaling may also interact with calcium channels, membrane excitability and secretory-vesicle processes.
Modified GRF(1–29) differs from native GHRH(1–29) through four commonly described amino-acid substitutions.
Those substitutions may influence resistance to selected proteolytic enzymes.
Modified GRF(1–29) lacks the DAC extension used in true CJC-1295 with DAC.
Growth Hormone-Releasing Hormone Receptor Research
The growth hormone-releasing hormone receptor is a class B G-protein-coupled receptor.
It is expressed prominently on anterior pituitary somatotroph cells.
Receptor activation is commonly associated with Gs signaling and cyclic AMP production.
Cyclic AMP may activate protein kinase A and contribute to hormone synthesis and secretion.
GHRH-receptor signaling may also influence intracellular calcium and membrane excitability.
Modified GRF(1–29) may be investigated using receptor-binding assays, cyclic AMP measurements, reporter systems and pituitary-cell models.
Receptor abundance and coupling efficiency may vary between experimental systems.
Receptor-selective antagonists or genetic methods may help establish pathway dependence.
Growth hormone-releasing hormone receptor.
GHRH-R or GHRHR.
Class B G-protein-coupled receptor.
Gs.
Cyclic AMP.
Anterior pituitary somatotroph.
Pituitary Somatotroph Research
Somatotroph cells are endocrine cells within the anterior pituitary.
They synthesize, store and release growth hormone.
Somatotroph activity is influenced by GHRH, somatostatin, ghrelin-associated signaling and endocrine feedback.
GHRH-receptor and GHS-R1a signaling may converge on intracellular pathways involved in hormone release.
Primary pituitary cells, pituitary tissue preparations and engineered cell lines may produce different experimental responses.
Cell differentiation, receptor expression and secretory-vesicle content should be documented.
Growth hormone measurements should be normalized to cell number, protein content or another validated reference where appropriate.
Cell viability should be assessed alongside secretory measurements.
Dual-Receptor Pathway Research
The rationale for studying Ipamorelin with Modified GRF(1–29) is based on activation of two separate upstream receptor systems.
Ipamorelin represents GHS-R1a-associated signaling.
Modified GRF(1–29) represents GHRH-receptor-associated signaling.
Both pathways may influence pituitary growth hormone-associated secretion.
Convergence at one physiological output does not mean the two peptides are chemically or functionally interchangeable.
Combination experiments should include Ipamorelin alone, Modified GRF(1–29) alone, the complete blend and vehicle controls.
A larger response in the blend condition may reflect additivity, altered receptor sensitivity, temporal alignment or true synergistic interaction.
Those possibilities require formal experimental differentiation.
A combined response that exceeds either individual peptide does not independently prove synergy. The observed response must be compared with the response predicted under a predefined additive model.
Cyclic AMP Signaling Research
Cyclic adenosine monophosphate, abbreviated cyclic AMP or cAMP, is an intracellular second messenger.
GHRH-receptor activation is commonly associated with Gs-protein signaling and adenylyl cyclase activation.
Adenylyl cyclase converts ATP into cyclic AMP.
Increased cyclic AMP may activate protein kinase A.
Protein kinase A may influence transcription, ion channels, secretory vesicles and hormone release.
Modified GRF(1–29) may be evaluated using cyclic AMP immunoassays, biosensors or reporter systems.
Assay timing is important because second-messenger responses may occur rapidly.
Phosphodiesterase activity may influence the magnitude and duration of cyclic AMP measurements.
Cell-free interference controls should determine whether either peptide affects assay detection chemistry.
Intracellular Calcium Research
GHS-R1a activation is commonly associated with phospholipase C and intracellular calcium signaling.
Calcium mobilization may influence membrane excitability and secretory-vesicle release.
Ipamorelin-associated receptor activity may be investigated using fluorescent calcium indicators or electrophysiological methods.
Calcium responses may occur within seconds or minutes and require suitable temporal resolution.
Dye loading, baseline fluorescence and receptor expression may influence assay performance.
High peptide concentrations may produce nonspecific effects that should be distinguished from receptor-mediated signaling.
GHS-R1a antagonists or receptor-negative cells may help determine pathway dependence.
Combined cyclic AMP and calcium measurements may support investigation of pathway convergence.
Growth Hormone Release Research
Pituitary somatotroph cells provide controlled experimental systems for studying receptor-dependent secretory responses.
GHRH-receptor and GHS-R1a signaling may be evaluated through defined biochemical, cellular and endocrine-model measurements.
Potential endpoints include secretory response magnitude, response timing, receptor activation, cyclic AMP, intracellular calcium and related downstream markers.
Combination studies should include Ipamorelin-alone, Modified GRF(1–29)-alone and complete-blend conditions when attribution of a response is required.
Secretory measurements should be interpreted alongside receptor expression, cell viability, assay timing and appropriate controls.
Observed hormone-associated responses in laboratory models do not establish safety, efficacy or suitability for human administration.
Temporal Secretory-Response Research
Secretory responses in pituitary models may be transient rather than constant.
Response amplitude, duration, timing and baseline secretion represent separate experimental variables.
Modified GRF(1–29) lacks the DAC structure designed for prolonged albumin association and should be studied separately from DAC-containing analogues.
Ipamorelin may be investigated as a second receptor-directed stimulus within controlled temporal-response experiments.
Serial sampling may be required to characterize transient changes and calculate integrated response over time.
Sparse sampling may miss short-lived peaks or create misleading comparisons.
Sampling frequency and temporal-analysis methods should be predefined before interpretation.
Downstream Endocrine-Signaling Research
IGF-1 and IGF-binding proteins may be evaluated as downstream endocrine markers in selected growth-hormone-axis research models.
Total IGF-1, free IGF-1, IGFBP-3 and related binding-protein measurements represent distinct experimental endpoints.
Downstream marker changes may occur on a different timeline from acute receptor or secretory responses.
A change in one downstream endocrine marker does not establish mechanism, clinical significance or suitability for personal use.
Downstream measurements should be interpreted alongside receptor activation, second-messenger signaling, assay timing and appropriate controls.
Somatostatin and Inhibitory Signaling Research
Somatostatin is an inhibitory regulator of pituitary growth hormone secretion.
Its receptor signaling may oppose stimulatory inputs from GHRH and growth hormone secretagogues.
The balance between stimulatory and inhibitory pathways may influence the magnitude of an observed response.
Isolated receptor assays do not reproduce every hypothalamic and pituitary feedback relationship.
Intact endocrine models may therefore produce different results from engineered receptor cell lines.
Somatostatin-receptor agonists or antagonists may be used as pathway-specific controls.
Changes in growth hormone release should not automatically be interpreted as direct changes in somatostatin synthesis or release.
Endocrine Feedback Research
Growth hormone and IGF-1 participate in feedback systems that influence hypothalamic and pituitary signaling.
Elevated downstream signals may alter GHRH, somatostatin or receptor responsiveness.
Acute receptor assays may not reproduce longer-term endocrine feedback.
Repeated-exposure models may differ from single-exposure experiments.
Receptor desensitization, internalization and changes in gene expression may influence repeated responses.
Baseline endocrine state should be documented when interpreting hormone-release data.
Nutritional status, glucose availability, insulin-associated signaling and circadian timing may influence experimental outcomes.
Ipamorelin Selectivity Research
Ipamorelin has been investigated as a selective growth hormone secretagogue relative to earlier compounds in the same research category.
Selectivity is an experimental property that depends on the receptors, concentrations and endpoints tested.
Receptor selectivity does not eliminate the possibility of indirect downstream endocrine effects.
Growth hormone, adrenocorticotropic hormone, cortisol-associated markers and prolactin-associated measurements may be evaluated independently.
Absence of a response in one assay does not prove universal absence of activity.
Receptor-panel testing and concentration-response analysis provide stronger selectivity evidence than one isolated measurement.
Ipamorelin vs. Ibutamoren Clarification
Ipamorelin and Ibutamoren are chemically distinct compounds.
Ipamorelin is a synthetic pentapeptide.
Ibutamoren, commonly identified as MK-677, is a non-peptide small molecule.
Both may be investigated in GHS-R1a-associated systems.
They differ in molecular structure, analytical behavior, receptor pharmacology and experimental exposure profile.
Ipamorelin should not be described as MK-677.
Experimental data from one compound should not automatically be applied to the other.
Structure–Activity Considerations
The biological activity of each blend component depends on its specific sequence, stereochemistry and terminal structure.
Ipamorelin contains nonstandard amino-acid residues and D-configured residues that contribute to its defined molecular identity.
Substitution with corresponding L-amino acids may alter receptor affinity or peptide stability.
Removal of the C-terminal amide would produce a chemically different Ipamorelin-related molecule.
Modified GRF(1–29) contains four substitutions relative to native GHRH(1–29).
Reversing those substitutions produces a different peptide more closely related to Sermorelin.
Adding a DAC-associated lysine extension creates a different CJC-1295 molecular form.
Truncation, sequence scrambling or terminal modification may alter receptor interaction, stability and chromatography.
Defined pentapeptide containing nonstandard residues and a C-terminal amide.
Defined 29-residue GHRH analogue with four commonly described substitutions.
Native GHRH(1–29)-related peptide without the four Modified GRF substitutions.
Includes an additional albumin-binding drug-affinity-complex structure.
May help evaluate dependence on sequence order.
Altered terminal chemistry produces distinct molecular forms.
Potential Laboratory Research Applications
Evaluation of Ipamorelin-associated ghrelin-receptor signaling.
Evaluation of Modified GRF(1–29)-associated GHRH-R signaling.
Investigation of simultaneous GHS-R1a and GHRH-R activation.
Study of pituitary cells involved in growth hormone synthesis and release.
Measurement of controlled receptor-associated secretory responses and kinetics.
Evaluation of transient secretory-response amplitude, timing and duration.
Measurement of GHRH-receptor-associated second-messenger signaling.
Evaluation of GHS-R1a-associated intracellular calcium responses.
Investigation of PKA, PKC and related intracellular pathways.
Measurement of IGF-1 and binding-protein endpoints within controlled laboratory models.
Investigation of interactions between convergent receptor pathways.
Evaluation of inhibitory regulation within the growth hormone axis.
Investigation of growth hormone and IGF-1-associated feedback systems.
Comparison of individual peptide conditions with the complete blend.
Evaluation of observed combination responses against additive predictions.
Characterization of component-specific and blend response curves.
Comparison of rapid receptor signaling and delayed downstream effects.
Evaluation of GHS-R1a and GHRH-R pathway dependence.
Measurement of each intact peptide during experimental incubation.
Evaluation of component-specific enzymatic degradation.
Separation of two peptide components and related molecular species.
Component-specific molecular identity and degradation analysis.
Quantitative evaluation of relative component composition.
Evaluation of peptide loss to containers, plates, filters and tubing.
Why Researchers May Select the 5MG / 5MG Blend
Provides a standardized nominal research quantity containing two labeled peptide components.
Contains 5MG of Ipamorelin and 5MG of Modified GRF(1–29).
Represents GHS-R1a-associated and GHRH-receptor-associated signaling.
Supports technical replicates, biological replicates and repeated experiments.
Supports evaluation across multiple controlled blend concentrations.
Supports rapid receptor signaling, second-messenger and delayed downstream measurements.
Provides a defined blend for comparison with individual peptide controls.
Supports investigation of transient receptor-associated secretory patterns in controlled laboratory models.
May be divided among receptor, hormone, stability and analytical studies.
Supports HPLC, LC-MS and component-ratio method development.
Uses Modified GRF(1–29) without the albumin-binding DAC extension.
Supplied as dry dual-peptide material for controlled laboratory preparation.
Experimental Design Considerations
Confirm Both Component Quantities
Record 5MG of Ipamorelin and 5MG of Modified GRF(1–29) separately rather than relying only on the 10MG total blend designation.
Use Component-Specific Molar Calculations
The peptides have different molecular weights and require separate molar calculations.
Include Individual-Peptide Conditions
Test Ipamorelin alone and Modified GRF(1–29) alone before assigning a response to the combination.
Use a Concentration Matrix
Multiple concentrations of each component may be required to characterize additivity or interaction.
Confirm Receptor Expression
Verify GHS-R1a and GHRH-receptor expression in the selected cell or tissue model.
Include Receptor-Specific Antagonists
Pathway-selective antagonists may help identify the contribution of each receptor system.
Measure Rapid Second Messengers
Cyclic AMP and calcium responses may occur earlier than hormone release or gene-expression changes.
Use Serial Secretory Measurements
Transient receptor-associated secretory responses may be missed by isolated measurements.
Separate Acute and Delayed Endpoints
Receptor signaling, secretory responses and downstream endocrine markers may require different sampling schedules.
Control Nutritional and Endocrine State
Glucose, amino acids, insulin-associated conditions and baseline endocrine signals may influence experimental responses.
Account for Somatostatin
Inhibitory signaling may alter the apparent response to either stimulatory pathway.
Monitor Both Peptides Analytically
Component-specific LC-MS or chromatographic methods may determine whether both peptides remain intact.
Evaluate Surface Recovery
The two peptides may display different adsorption to tubes, filters or assay plates.
Control Assay Interference
Cell-free controls should determine whether either peptide alters optical, fluorescent or immunoassay detection.
Predefine the Interaction Model
Select a justified additive or interaction framework before describing an observed response as synergistic.
Use Orthogonal Endpoints
Receptor, second-messenger, secretory-response and analytical measurements may provide stronger evidence together.
Predefine Statistical Analysis
Replicate structure, exclusion criteria, normalization and multiple-comparison methods should be specified before analysis.
Recommended Experimental Controls
Establishes baseline behavior without peptide exposure.
Determines whether the preparation medium influences the endpoint.
Defines the response associated with the GHS-R1a component.
Defines the response associated with the GHRH-receptor component.
Evaluates simultaneous exposure to both peptide components.
Supports formal interaction and additivity analysis.
Tests dependence on the Ipamorelin-associated receptor pathway.
Tests dependence on the Modified GRF-associated receptor pathway.
Evaluates combined receptor dependence.
Confirms functional GHRH-receptor assay performance.
Confirms functional growth hormone secretagogue receptor signaling.
Evaluates inhibitory regulation of hormone release.
Confirms second-messenger assay responsiveness.
Confirms detection of rapid intracellular calcium changes.
Accounts for incubation duration and sample handling.
Distinguishes receptor responses from altered cell survival.
Supports normalization of secreted hormone measurements.
Help identify receptor-dependent activity.
Determines whether either peptide changes assay detection chemistry.
Identifies background from solvents, buffers, columns and instruments.
Supports component-specific retention and molecular-mass comparison.
Supports component-specific identity and chromatographic comparison.
Confirms whether both intact peptides remain detectable during incubation.
Measures component-specific loss during storage and sample preparation.
May distinguish Modified GRF(1–29) from true CJC-1295 with DAC.
Supports comparison with unmodified human GHRH(1–29)-related peptide.
Analytical Characterization
Analytical characterization of IPA / CJC-1295 No DAC requires component-specific evaluation.
High-performance liquid chromatography may evaluate chromatographic composition, retention behavior and related peptide species.
Liquid chromatography–mass spectrometry may support confirmation of molecular species consistent with each expected intact mass.
Tandem mass spectrometry may provide fragment-ion evidence supporting the identity of each component.
Ipamorelin and Modified GRF(1–29) may display different ultraviolet-response factors.
One dominant chromatographic peak should not automatically be interpreted as representing the complete blend.
Peak-area percentage should not be used as a direct 1:1 mass-ratio measurement unless detector-response factors have been validated.
Counterions, water and residual solvents may contribute to total material mass without representing peptide-equivalent content.
Functional receptor activity cannot be established through HPLC or molecular-mass agreement alone.
Total vial mass, Ipamorelin-equivalent content, Modified GRF(1–29)-equivalent content, blend ratio, chromatographic composition, molecular identity, sequence integrity, counterion form, stability and receptor bioactivity are separate analytical attributes.
HPLC Analysis of IPA / CJC-1295 No DAC
Reverse-phase high-performance liquid chromatography may separate Ipamorelin, Modified GRF(1–29) and related peptide species.
Ipamorelin contains aromatic nonstandard residues and may display substantial hydrophobic retention.
Modified GRF(1–29) is longer and contains a broader distribution of polar, charged and hydrophobic residues.
A gradient suitable for one component may not provide optimal separation for the other.
Method development may require adjustment of column chemistry, starting organic content, gradient slope, temperature, mobile-phase pH and ion-pairing conditions.
Detection wavelength may influence the relative response of the two peptides.
Component-specific reference standards may support retention-time assignment.
Peak-area percentage is a chromatographic measurement and does not independently determine component mass.
Retention time alone does not establish molecular identity and should be supported by mass spectrometry or another orthogonal method.
LC-MS and Molecular Identity
Liquid chromatography–mass spectrometry combines chromatographic separation with mass-to-charge analysis.
Ipamorelin may produce singly and multiply protonated ions depending on source and mobile-phase conditions.
Modified GRF(1–29) may produce a broader multiply charged ion envelope because of its larger size and multiple ionizable residues.
Deconvolution may be used to estimate the intact neutral molecular mass of Modified GRF(1–29).
Sodium, potassium and other adduct-associated ions may appear.
Degradation products may produce lower-mass ions requiring chromatographic separation and sequence analysis.
Tandem mass spectrometry may provide sequence-associated fragment evidence for each component.
Molecular-mass agreement does not independently establish stereochemistry, component quantity, blend ratio or biological activity.
The two components should be integrated and reported independently during quantitative analysis.
Functional Bioactivity Research
Chemical identity does not independently establish functional receptor activity.
Ipamorelin activity may be evaluated through GHS-R1a reporter assays, calcium mobilization or receptor-dependent hormone-release systems.
Modified GRF(1–29) activity may be evaluated through GHRH-receptor cyclic AMP assays or somatotroph hormone-release systems.
Blend activity requires evaluation of both receptor pathways.
A response at only one receptor does not establish full dual-component bioactivity.
Combined growth hormone release does not independently verify the identity or quantity of both peptides.
Component-specific analytical and functional tests provide stronger characterization than one combined endpoint.
Receptor-negative cells and receptor-selective antagonists may help confirm pathway dependence.
IPA / CJC-1295 No DAC Stability Considerations
The two peptide components may have different stability profiles.
Stability may be influenced by temperature, moisture, light, oxygen, pH, enzymes, concentration and container material.
Potential degradation pathways include peptide-bond hydrolysis, proteolytic cleavage, oxidation, deamidation, terminal cleavage and surface adsorption.
Modified GRF(1–29) contains more peptide bonds and potential degradation sites than the shorter Ipamorelin molecule.
Ipamorelin’s nonstandard residues may alter susceptibility to selected enzymes but do not make the peptide universally resistant to degradation.
Lyophilization removes a substantial portion of water and may support stability relative to prolonged solution storage.
Once placed into solution, buffer composition, pH, microbial contamination and container interactions may become increasingly important.
Biological matrices may contain peptidases capable of generating shorter component fragments.
Solution appearance does not establish the molecular integrity of either peptide.
Stability should be evaluated using component-specific HPLC, LC-MS or another validated analytical method.
Potential Degradation Pathways
Peptidases may generate shorter peptide fragments from either component.
Loss of N-terminal residues creates distinct molecular species.
Loss of terminal residues or amidation changes the defined peptide structure.
Water-dependent reactions may affect intact peptide backbones over time.
Selected residues may undergo condition-dependent oxidative modification.
Asparagine- or glutamine-associated regions may undergo condition-dependent changes.
Stress conditions may produce related species with altered chromatography.
Either peptide may bind to glass, plastic, filters, plates or tubing.
Proteins and other biological components may affect free-peptide recovery.
Concentration and solution conditions may influence molecular association.
Counterion content may influence total material mass and analytical behavior.
Related species may overlap with one or both intact peptide peaks.
One peptide may degrade or adsorb more rapidly than the other.
Contamination may alter peptide integrity and invalidate experiments.
Laboratory Storage
Lyophilized IPA / CJC-1295 No DAC 10MG should be maintained in a cool, dry and dark laboratory environment protected from unnecessary heat, moisture and direct light.
Longer-term storage should follow the product label, available lot documentation and validated institutional procedures.
Repeated temperature cycling should be minimized because it may introduce condensation and variable environmental exposure.
When condensation is possible, sealed material should be allowed to equilibrate under controlled laboratory conditions before opening.
Prepared research solutions are generally less stable than dry lyophilized material.
Solution stability depends on pH, buffer composition, oxygen exposure, temperature, concentration, container material and storage duration.
The two peptide components may degrade at different rates and should be monitored independently when stability is critical.
Storage information is provided solely for preservation of laboratory research material and is not a preparation, dosing or administration protocol.
Laboratory Handling
IPA / CJC-1295 No DAC 10MG should be handled only by trained research personnel using procedures appropriate for synthetic peptide mixtures.
Researchers should document the lot identifier, component quantities, preparation date, solvent or buffer, calculated concentrations, storage history and handling cycles.
Calculations should account for Ipamorelin and Modified GRF(1–29) independently.
Calibrated balances, pipettes and analytical instruments should be used when quantitative accuracy is required.
Small-volume transfer error, incomplete mixing and surface adsorption may create differences between calculated and recovered concentrations.
Low-binding laboratory materials may be evaluated when adsorption has been demonstrated experimentally.
Filtration methods should be tested for recovery of both peptide components before routine use.
Personal protective equipment, containment procedures and waste disposal should follow institutional requirements and laboratory risk assessment.
IPA / CJC-1295 No DAC Compared With Related Research Compounds
Modified GRF(1–29) lacks the albumin-binding DAC extension present in true CJC-1295 with DAC.
Both contain 29 residues, but Modified GRF incorporates four amino-acid substitutions.
Modified GRF is a 29-residue analogue, while Tesamorelin is a modified 44-residue GHRH analogue.
Both are GHS-R1a-associated secretagogues but have different structures and experimental selectivity profiles.
Ipamorelin is a pentapeptide, while Ibutamoren is a non-peptide small molecule.
The blend includes a second GHRH-receptor-directed peptide component.
The blend includes a second GHS-R1a-directed peptide component.
Neither peptide is growth hormone; both are investigated as upstream signaling ligands.
CJC-1295 No DAC vs. CJC-1295 With DAC
CJC-1295 No DAC and CJC-1295 with DAC should not be treated as identical compounds.
The non-DAC material generally corresponds to Modified GRF(1–29).
True CJC-1295 with DAC includes an additional reactive drug-affinity-complex structure associated with albumin binding.
Albumin association may substantially alter experimental exposure duration, distribution and pharmacokinetic behavior.
Modified GRF(1–29) lacks this DAC extension.
Analytical standards, molecular weights, chromatographic methods and experimental timelines must therefore be selected separately.
Findings from a DAC-containing compound should not automatically be applied to the non-DAC peptide.
Modified GRF(1–29) vs. Tesamorelin
Modified GRF(1–29) and Tesamorelin are both synthetic GHRH-receptor-directed research peptides.
Modified GRF contains 29 residues derived from the active N-terminal region of human GHRH.
Tesamorelin is based on the longer 44-residue human GHRH sequence and contains a distinct N-terminal modification.
The peptides differ in length, molecular weight, sequence, modification strategy and potential degradation behavior.
Equal mass quantities do not represent equal molecule numbers.
Comparative research should use peptide-specific molar normalization and independent analytical standards.
Modified GRF(1–29) vs. Sermorelin
Sermorelin corresponds to human GHRH(1–29).
Modified GRF(1–29) retains the same general peptide length but incorporates substitutions at positions 2, 8, 15 and 27.
These substitutions alter the peptide’s chemical identity and may influence enzymatic stability.
Sermorelin and Modified GRF(1–29) should not be used as interchangeable analytical standards.
Comparative studies may evaluate receptor potency, cyclic AMP production, peptide degradation, hormone release and response duration.
Related Research Products and Resources
Scientific Research Resources
Frequently Asked Questions
What is IPA / CJC-1295 No DAC 10MG?
It is a lyophilized dual-peptide research blend containing 5MG of Ipamorelin and 5MG of Modified GRF(1–29).
What does IPA mean in the product name?
IPA is a commonly used abbreviation for Ipamorelin.
How much Ipamorelin is in the blend?
The vial contains a nominal 5MG quantity of Ipamorelin.
How much CJC-1295 No DAC is in the blend?
The vial contains a nominal 5MG quantity of CJC-1295 No DAC, also identified as Modified GRF(1–29).
What is the total research quantity?
The vial contains a total nominal research quantity of 10MG.
What is the blend ratio?
The product contains a 1:1 labeled mass ratio of 5MG Ipamorelin to 5MG Modified GRF(1–29).
Does a 1:1 mass ratio mean equal molecule numbers?
No. The peptides have different molecular weights, so equal mass quantities do not represent equal molar quantities.
What is CJC-1295 No DAC?
CJC-1295 No DAC is the common research-market name generally used for Modified GRF(1–29).
What does No DAC mean?
It means the peptide does not contain the albumin-binding drug-affinity-complex extension found in true CJC-1295 with DAC.
Is CJC-1295 No DAC the same as CJC-1295 with DAC?
No. The compounds differ in molecular structure and experimental exposure profile.
What type of peptide is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue.
How many amino acids does Ipamorelin contain?
Ipamorelin contains five amino-acid residues.
What receptor is associated with Ipamorelin?
Ipamorelin is investigated primarily through GHS-R1a, commonly called the ghrelin receptor.
What receptor is associated with Modified GRF(1–29)?
Modified GRF(1–29) is investigated primarily through the growth hormone-releasing hormone receptor.
How many amino acids does Modified GRF(1–29) contain?
Modified GRF(1–29) contains twenty-nine amino-acid residues.
What is Ipamorelin’s molecular formula?
The referenced molecular formula is C38H49N9O5.
What is Ipamorelin’s molecular weight?
Its referenced molecular weight is approximately 711.9 g/mol.
What is the PubChem CID for Ipamorelin?
The PubChem Compound ID is 9831659.
What is the PubChem CID for CJC-1295 No DAC?
PubChem lists the CJC-1295 Without DAC record under Compound ID 91976842.
Is Ipamorelin the same as Ibutamoren?
No. Ipamorelin is a peptide, while Ibutamoren is a chemically distinct non-peptide small molecule.
Is Modified GRF(1–29) the same as Sermorelin?
No. Both contain twenty-nine residues, but Modified GRF incorporates four commonly described amino-acid substitutions.
Is Modified GRF(1–29) the same as Tesamorelin?
No. Modified GRF contains twenty-nine residues, while Tesamorelin is a differently modified forty-four-residue GHRH analogue.
Do both blend components use the same receptor?
No. Ipamorelin is associated with GHS-R1a, while Modified GRF(1–29) is associated with GHRH-R.
Does a larger combined response prove synergy?
No. Synergy requires comparison with a formally defined additive-response prediction.
Why are individual-component controls important?
They allow researchers to distinguish the response associated with each peptide from the combined condition.
Can the blend be studied in cyclic AMP assays?
Modified GRF(1–29)-associated GHRH-receptor activity may be investigated through cyclic AMP measurements.
Can the blend be studied in calcium-flux assays?
Ipamorelin-associated GHS-R1a activity may be investigated through intracellular calcium measurements.
Can one HPLC peak confirm both peptide components?
No. The components should be separated, identified and quantified using validated component-specific methods.
Does LC-MS identity prove receptor bioactivity?
No. Molecular identity and functional receptor activity are separate properties.
Why must each component be calculated separately?
Ipamorelin and Modified GRF(1–29) have different molecular weights despite being present at equal labeled mass.
Does the 10MG designation represent a recommended dose?
No. The 10MG designation identifies total nominal laboratory research quantity only and does not represent a recommended amount, dosage, schedule or administration instruction.
Is IPA / CJC-1295 No DAC an approved pharmaceutical product?
No. This product is supplied solely as laboratory research material and is not represented as an FDA-approved drug.
Is IPA / CJC-1295 No DAC intended for human use?
No. It is strictly for controlled laboratory research and is not intended for human or veterinary administration.
Research-Use Notice
IPA / CJC-1295 No DAC 10MG is supplied exclusively as laboratory research material. It is not a drug, finished pharmaceutical product, prescription medication, compounded preparation, food, dietary supplement, cosmetic or consumer product. It is not intended for human consumption, self-administration, medical use, veterinary use, household use, diagnostic use, topical application or therapeutic use.
This research blend contains a nominal 5MG quantity of Ipamorelin and a nominal 5MG quantity of CJC-1295 No DAC, also identified more precisely as Modified GRF(1–29), for a total nominal research quantity of 10MG.
The term CJC-1295 No DAC is used on this page as a familiar research-market identifier for the non-DAC peptide generally described as Modified GRF(1–29). This material should not be represented as chemically identical to true CJC-1295 containing a drug-affinity-complex modification.
References to growth hormone, GHRH, ghrelin, GHS-R1a, pituitary function, somatotroph cells, IGF-1, cyclic AMP, calcium signaling, temporal secretory responses, endocrine feedback or published scientific findings are provided solely to describe areas of biochemical, cellular, analytical and preclinical investigation.
These references do not constitute medical claims, treatment recommendations or representations regarding the safety or effectiveness of this research material.
Findings from receptor, cellular, tissue or animal research should not be interpreted as establishing safety, efficacy, dosing, bioavailability or suitability for administration of this product to humans or animals.
No information on this page should be interpreted as instructions for reconstitution, dosing, administration, injection, self-experimentation, hormone enhancement, athletic-performance enhancement, body-composition modification, anti-aging use, diagnosis, prevention, mitigation or treatment of any disease or condition.
The 5MG / 5MG and 10MG designations identify nominal laboratory research quantities only. They do not represent recommended amounts, dosages, schedules or administration instructions.
This material should be handled only by qualified research personnel in an appropriately controlled laboratory environment. Researchers are responsible for confirming the identity and quantity of both peptide components, reviewing available lot-specific analytical documentation, selecting suitable analytical methods, determining suitability for their experimental design and complying with all applicable institutional, local, state and federal requirements.
Related products
Research Compounds
Research Compounds
Research Compounds
Research Compounds
Research Compounds
Research Compounds
Research Compounds
Research Compounds